Hundreds of patients with a type of aggressive skin cancer will be offered a targeted therapy on the NHS in England and Wales, which reduces the risk of it returning.
Regulatory
FDA grants Keytruda priority review for Merkel cell carcinoma
The FDA granted priority review designation to a supplemental biologics license application of pembrolizumab for the treatment of pediatric and adult patients with locally recurrent advanced or metastatic Merkel cell carcinoma…
FDA Approves Encorafenib and Binimetinib Combo for Melanoma With BRAF Mutations
The FDA approved the use of encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma) in combination for patients
FDA approves combo treatment for melanoma
The combination of encorafenib and binimetinib (Braftovi and Mektovi) has been granted approval by the U.S. Food and Drug Administration